Moleculomics has launched its flagship in silico drug discovery platform, Human3DProteome.
Human3DProteome is a comprehensive platform for whole system drug discovery, drug repurposing and toxicity screening.
Human3DProteome is a breakthrough technology for rapid discovery of better and safer drug compounds – a comprehensive in silico platform of the entire human proteome (all the receptors,
A spin out company of the Institute of Life Science at Swansea University has recently delivered an in silico drug discovery software platform for the UK Ministry of Defence.
The software tool named TargetPath, developed for the identification of protein antibiotic or anti-bacterial target(s) within a pathogen, will be used by the scientists of Defence,
Getting better drugs to market faster, and at a fraction of the cost, is a step closer thanks to technology for speeding up the testing process, which is being developed by a Swansea University spin-out company, Moleculomics.
The company has been developing comprehensive platforms of computer-generated models for protein structures in the human body.
The British Yeast Group Meeting 2016 was held at Swansea University and hosted by the Centre
for Cytochrome P450 Biodiversity. The conference attracted an international mix of attendees with talks ranging from fundamental eukaryotic biology to yeast as a model for human disease.
During the event, Moleculomics CEO Dr Jonathan Mullins unveiled Yeast3DProteome: A comparative structural bioinformatics platform for yeasts.
Moleculomics were proud to sponsor the 2016 British Science Festival, hosted by Swansea University this year.
The British Science Festival is Europe’s longest-standing national event which connects people with scientists, engineers, technologists and social scientists. Organised by the British Science Association (BSA), the event was first held in York in 1831 and then annually at cities across the UK.
Moleculomics founder and CEO Dr Jonathan Mullins was proud to be invited as keynote speaker at the International conference on Clinical Sciences and Drug Discovery (CSDD-2016) in Dundee earlier this year.
Highly aligned to the evolution of Moleculomics, the focus of CSDD-2016 lies in the translation of academic research findings into industry-driven drug development.
JOB: Bioinformatician Research Assistant
LOCATION: Laval, Quebec ⧉
JOB TERM: 1 years fixed term with opportunity for continuation
Moleculomics is seeking to employ a bioinformatician for the delivery of a strategically important project for the development of our fast growing company.
In this role you will be responsible for the technical delivery of a project spanning both high throughput protein structural modelling and predicted interaction of resulting protein structures with large libraries of small molecules.
Moleculomics, a company who specialise in high-throughput prediction of molecular interactions using cutting-edge in silico modelling and screening tools, has recently completed a project funded by the Defence Science and Technology Laboratory’s (Dstl) Centre for Defence Enterprise (CDE). It focuses on the identification of host-pathogen interactions which can be manipulated in order to devise novel therapies to meet the UK’s current and future defence and security needs.
Montreal, Canada, March 3, 2016 – Moleculomics, a UK university spin-out company offering powerful high-throughput prediction of small molecule – protein interactions using cutting-edge in silico modelling and screening tools, is pleased to announce the official opening of its North American sales and support office within the NEOMED Institute in Laval,